Comparative Pharmacology
Head-to-head clinical analysis: EMTRIVA versus STAVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRIVA versus STAVUDINE.
EMTRIVA vs STAVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
Nucleoside reverse transcriptase inhibitor; intracellularly phosphorylated to active triphosphate which competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
Emtricitabine 200 mg orally once daily.
30 mg orally every 12 hours (for weight ≥60 kg: 40 mg every 12 hours)
None Documented
None Documented
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Clinical Note
moderateStavudine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Stavudine."
Clinical Note
moderateStavudine + Didanosine
"The risk or severity of adverse effects can be increased when Stavudine is combined with Didanosine."
Clinical Note
moderateDoxorubicin + Stavudine
"The therapeutic efficacy of Stavudine can be decreased when used in combination with Doxorubicin."
Clinical Note
moderateHydroxyurea + Stavudine
Terminal elimination half-life is 1.0–1.6 hours in adults; intracellular active triphosphate half-life is 3.5–7 hours, supporting twice-daily dosing.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Renal (approximately 70% unchanged, 30% as metabolites); biliary/fecal minimal.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Stavudine."